Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: GARY P GROBBEL who wrote (90174)	10/8/2009 10:06:41 AM
From: GARY P GROBBEL	Read Replies (1) \| Respond to of 120415

GTHP.PK-$.60--- B: Guided Therapeutics obtains $2.5 million research grant from N CI ( Datamonitor ) B: Guided Therapeutics obtains $2.5 million research grant from NCI ( Datamonito r ) Oct 08, 2009 (Datamonitor via COMTEX) -- Guided Therapeutics, a US-based medical technology company, has received a $2.5 million matching grant from the National Cancer Institute to bring to market and expand the array features for its LightTouch non-invasive cervical cancer detection technology. The award provides resources to complete the regulatory process and begin manufacturing ramp up for the device and single-patient-use disposable. Including the new award, the company has been awarded approximately $6 million in six consecutive grants from the National Cancer Institute (NCI) to develop the new, pain-free test for detecting cervical disease. According to Guided Therapeutics, the GT LightTouch technology systematically and rapidly scans the cervix to identify cancer and pre-cancer painlessly and non-invasively, by analyzing the wavelengths of light reflected from cervical tissue. The technology distinguishes between normal and diseased tissue, by detecting biochemical and morphological changes at the cellular level. Unlike Pap or HPV tests, the LightTouch test does not require a tissue sample or laboratory analysis, and is designed to provide results immediately. The technology is designed as a device employing a single-use disposable patient interface, the company added. Mark Faupel, president and CEO of Guided Therapeutics, said: "This grant provides significant non-dilutive resources for us to begin manufacturing LightTouch devices and disposables for an international launch, as we simultaneously complete the FDA pre-market approval application process." datamonitor.com Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon Copyright (C) 2009 Datamonitor. All rights reserved * end of story *